证券代码：300171 证券简称：东富龙 公告编号：2023-045 东富龙科技集团股份有限公司 第六届董事会第四次（临时）会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届董事会第四次（临 时）会议于 2023 年 9 月 24 日以电话、书面方式通知各位董事，会议于 2023 年 9 月 28 日（星期四）以通讯表决方式召开。本次董事会会议应出席董事 9 名， 实际出席会议董事 9 名。会议由董事长郑效东先生主持，董事会秘书王艳女士列 席了本次会议。会议的召开符合《中华人民共和国公司法》及《公司章程》的有 关规定。会议经认真审议，通过如下议案： 一、审议通过《关于聘任公司财务总监的议案》 经公司董事会提名委员会提名和资格审核，审计委员会审议通过，公司董事 会同意聘任陆德华先生担任公司财务总监，任期自本次董事会审议通过之日起至 第六届董事会届满之日止。 赞成票，9 票，占出席会议董事的 100%；反对票，0 票，占出席会议董事的 0%；弃权票，0 票，占出席会议董事的 0%。 《关于聘任公司财务 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-046 东富龙科技集团股份有限公司 关于聘任公司财务总监的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）于2023年9月28日召开 第六届董事会第四次（临时）会议，审议通过《关于聘任公司财务总监的议案》， 根据《中华人民共和国公司法》《公司章程》等相关规定，经公司董事会提名委 员会提名和资格审核，审计委员会审议通过，同意聘任陆德华先生（简历见附件） 担任公司财务总监，任期自本次董事会审议通过之日起至第六届董事会届满之日 止。 陆德华先生具备与其行使职权相适应的任职条件，不存在有《中华人民共和 国公司法》及其他法律法规规定的不得担任公司财务总监的情况。 特此公告。 东富龙科技集团股份有限公司 董事会 陆德华先生，1981年11月出生，中国国籍，无永久境外居留权，数学专业、 经济学专业理学双学士学位，中级会计师，管理会计师。2012年7月入职公司， 历任东富龙拓溥财务主管、分装机产品部财务主管、注射剂事业部财务经理、财 务中心财务经理、财务中心副总监 ...

郜志坚先生的原定任期届满日为 2026 年 2 月 3 日。截至本公告披露日，郜 志坚先生及其关联人未持有公司股份，不存在其应当履行而未履行的承诺事项。 证券代码：300171 证券简称：东富龙 公告编号：2023-044 东富龙科技集团股份有限公司 关于公司财务总监辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 东富龙科技集团股份有限公司（以下简称 "公司"）董事会近日收到财务总 监郜志坚先生的书面辞职报告，郜志坚先生因个人原因申请辞去公司财务总监职 务。郜志坚先生辞职后不再担任公司任何职务。 根据《公司法》《公司章程》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等的有关规定，其辞职报告自送达董事会之日 起生效，郜志坚先生的辞职不会影响公司日常生产经营和财务管理等工作，公司 将按照规定尽快完成财务总监的聘任工作。 公司及董事会对郜志坚先生在担任财务总监期间为公司发展所做贡献表示 衷心的感谢。 特此公告。 东富龙科技集团股份有限公司 董事会 2023 年 9 月 8 日 ...

证券代码：300171 证券简称：东富龙 东富龙科技集团股份有限公司投资者关系活动记录表 编号：2023-004 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 | 通过"全景•路演天下"（http://rs.p5w.net）参与本次集体接待日暨业 | | 及人员姓名 | 绩说明会的广大投资者 | | 时间 | 2023 年 9 月 7 日 14：00—16：30 | | 地点 | "全景•路演天下"（http://rs.p5w.net）互动平台 | | | 董事长兼总经理：郑效东先生 | | 上市公司接待 | 独立董事：强永昌先生 | | 人员姓名 | 财务总监：郜志坚先生 | | | 副总经理兼董事会秘书：王艳女士 | | | 问题 1、公司的营业收入和净利润在今年上半年分别增长了约 21.58%和 | | | 5.82%，您认为这是由于哪些主要因素所推动？ | | | 答：2023 年上半年，面对复杂严峻的内外部环境，生物医药装备行业机 ...

公司董事会对保荐代表人胡朝峰先生在公司2022年度向特定对象发行A股 股票项目及持续督导期间所做出的贡献表示衷心的感谢。 附件：王天祺女士的简历 特此公告。 东富龙科技集团股份有限公司 董事会 证券代码：300171 证券简称：东富龙 公告编号：2023-043 东富龙科技集团股份有限公司 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"或"东富龙"）于2023年9月 5日收到中信证券股份有限公司（以下简称"中信证券"）关于更换持续督导 保荐代表人的书面函。中信证券为公司2022年度向特定对象发行A股股票项目 的保荐机构，原指定赵洞天先生、胡朝峰先生担任保荐代表人。现胡朝峰先生 因工作变动原因，不再担任公司持续督导保荐代表人。 为保证持续督导工作的有序进行，中信证券委派王天祺女士接替胡朝峰先 生担任公司持续督导工作的保荐代表人，继续履行相关职责。本次保荐代表人 变更后，公司2022年度向特定对象发行A股股票项目的持续督导保荐代表人为 赵洞天先生和王天祺女士，持续督导期至中国证券监督管理委员 ...

中信证券股份有限公司 关于东富龙科技集团股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：东富龙 | | --- | --- | | 保荐代表人姓名：赵洞天 | 联系电话：010-60838275 | | 保荐代表人姓名：王天祺 | 联系电话：010-60838144 | 一、保荐工作概述 | 项 目 | | 工作内容 | | | --- | --- | --- | --- | | 1.公司信息披露审阅情况 | | | | | （1）是否及时审阅公司信息披露文件 | | 是 | | | （2）未及时审阅公司信息披露文件的次数 | | 次 0 | | | 2.督导公司建立健全并有效执行规章制度的情 | | | | | 况 | | | | | （1）是否督导公司建立健全规章制度（包括但 不限于防止关联方占用公司资源的制度、募集 | | | | | | | 是 | | | 资金管理制度、内控制度、内部审计制度、关 | | | | | 联交易制度） | | | | | （2）公司是否有效执行相关规章制度 | | 是 | | | 3.募集资金监督情况 | | | | | ...

证券代码：300171 证券简称：东富龙 | --- | --- | |----------------|-----------------------| | | □特定对象调研 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | □现场参观 ■其他 电话会议 参与单位名称 及人员姓名 电话通讯方式与会名单请见附件 时间 2023 年 8 月 29 日 8：30—9：30 地点 电话会议 董事长兼总经理：郑效东 上市公司接待 财务总监：郜志坚 人员姓名 副总经理兼董事会秘书：王艳 投资总监：张盟 1、公司 2023 年半年度经营情况介绍。 答：2023 年半年度公司实现营业收入 29.51 亿元，较上年同期 增长 21.58%，归属于上市公司股东的净利润 4.26 亿元，较上年同期 增长 5.82%，归属于上市公司扣非后净利润 3.93 亿元，较上年同期 增 5.72%。国内收入 23.69 亿元，占比 80.3%；国际收入 5.81 亿元， 投资者关系活动主 占比 19.7%，国际占比与上年度相比有小幅度增长。 要内容介绍 2、请公司解读公司毛利率降低的原因 ...

Share Issuance and Capital Structure - The company issued 120,000,000 new shares to specific investors, increasing the total shares from 635,415,040 to 760,702,540, with the proportion of restricted shares rising from 31.66% to 42.36%[7] - The company's total share capital increased from 755,415,040 to 755,523,040 after the listing of 108,000 restricted shares from the 2021 incentive plan[8] - The company's total share capital further increased to 760,702,540 after the listing of 5,179,500 restricted shares from the second vesting period of the 2021 incentive plan[9] - The company received approval from the China Securities Regulatory Commission to issue 120,000,000 new shares to specific investors, which were listed on the Shenzhen Stock Exchange on January 13, 2023[26] - The company's total share capital increased from 635,415,040 shares to 755,415,040 shares after the issuance of 120,000,000 restricted shares to specific investors[93] - The company received approval from the China Securities Regulatory Commission (CSRC) for its private placement of A-shares on October 17, 2022[81][85] - The company issued 120,000,000 A-shares at a price of 20.57 yuan per share, raising a total of 2,468,400,000.00 yuan, with a net fundraising amount of 2,428,313,465.44 yuan[125] - The company issued 120,000,000 shares on December 20, 2022, at a price of 20.57, and they were listed on January 13, 2023[140] Restricted Stock Incentive Plan - The company completed the registration of 7.078 million restricted shares for the first vesting period of the 2021 restricted stock incentive plan, with 352 participants, and the shares became tradable on May 20, 2022[61] - The company held its sixth board meeting on April 26, 2023, approving the cancellation of some unvested restricted shares and the achievement of the second vesting period conditions for the 2021 restricted stock incentive plan[62] - The company implemented a restricted stock incentive plan in 2021, with adjustments made to the list of激励对象 and the number of shares granted[96][97][98] - The company's restricted shares increased by 419,351 due to the expiration of the term of office of certain directors and senior management[109] - The company's restricted shares increased by 93,750 due to the appointment of a new R&D director[109] - The company's restricted shares increased by 24,307,243 for specific investors such as the Advanced Manufacturing Industry Investment Fund II[100] - The company's restricted shares increased by 14,584,346 for specific investors such as Junhe Licheng Investment Management Center[100] - The company's restricted shares increased by 13,612,056 for specific investors such as Gaoyi Xiaofeng 2 Fund[100] Financial Performance and Metrics - The company's monetary funds decreased from 4,710,070,214.21 to 3,543,443,055.34 as of June 30, 2023[107] - The company's trading financial assets increased from 282,700,577.90 to 922,097,183.04 as of June 30, 2023[107] - The company's accounts receivable increased from 1,260,559,830.70 to 1,636,534,944.00 as of June 30, 2023[107] - The company's inventory decreased from 3,899,309,956.37 to 3,797,199,449.86 as of June 30, 2023[107] - The company's total current assets decreased from 11,264,291,322.75 to 10,823,334,932.34 as of June 30, 2023[107] - As of the reporting period, the company's total assets amounted to 13,219,848,446.31 yuan, with non-current assets totaling 2,396,513,513.97 yuan[121] - The company's long-term equity investments were valued at 140,255,968.34 yuan, and other equity instrument investments stood at 123,696,668.28 yuan[121] - The company's total liabilities were 5,314,550,261.43 yuan, with current liabilities accounting for 5,174,146,102.05 yuan[122] - The company's owner's equity totaled 7,905,298,184.88 yuan, with minority interests amounting to 218,956,579.73 yuan[122] - The company's fixed assets were valued at 768,392,408.08 yuan, and construction in progress was 552,008,214.27 yuan[121] - The company's contract liabilities amounted to 3,622,178,825.91 yuan, reflecting significant customer prepayments[121] - The company's monetary funds stood at 1,916,984,011.55 yuan, indicating strong liquidity[122] - The company's total equity attributable to the parent company was 7,686,341,605.15 yuan, with retained earnings of 2,887,600,796.49 yuan[122] - Total operating revenue for the first half of 2023 reached 2,950,710,728.63 yuan, a 21.6% increase compared to 2,426,943,177.90 yuan in the same period last year[148] - Operating costs for the first half of 2023 were 2,348,381,092.30 yuan, up 23.4% from 1,902,871,463.41 yuan in the first half of 2022[150] - Net profit for the first half of 2023 was 459,844,218.74 yuan, a 7.8% increase from 426,576,111.98 yuan in the same period last year[150] - R&D expenses for the first half of 2023 were 164,161,267.32 yuan, an 8.4% increase compared to 151,400,254.02 yuan in the first half of 2022[150] - Total liabilities as of the end of the first half of 2023 were 4,012,557,080.62 yuan, a decrease of 8.2% from 4,370,452,797.42 yuan at the end of the first half of 2022[148] - Total equity as of the end of the first half of 2023 was 6,862,284,529.82 yuan, a 1.5% increase from 6,759,579,250.37 yuan at the end of the first half of 2022[148] - Sales expenses for the first half of 2023 were 147,178,732.99 yuan, a 34.5% increase compared to 109,476,770.34 yuan in the first half of 2022[150] - Financial expenses for the first half of 2023 showed a net income of 48,211,350.46 yuan, compared to an expense of 11,718,166.99 yuan in the same period last year[150] - Credit impairment losses for the first half of 2023 were 77,293,706.63 yuan, an 88.1% increase from 41,109,684.85 yuan in the first half of 2022[150] - Total assets as of the end of the first half of 2023 were 10,874,841,610.44 yuan, a 2.3% decrease from 11,130,032,047.79 yuan at the end of the first half of 2022[148] - Net cash flow from operating activities was -2,135,895.49 yuan, compared to -11,739,484.85 yuan in the same period last year[166] - Net cash flow from investing activities was -756,130,260.48 yuan, a significant decrease from 344,659,574.67 yuan in the same period last year[166] - Net cash flow from financing activities was -116,145,225.49 yuan, compared to -179,853,956.20 yuan in the same period last year[166] - Total cash and cash equivalents at the end of the period were 3,533,937,375.54 yuan, down from 4,706,804,219.30 yuan at the beginning of the period[166] - Revenue for the first half of 2023 was 2,362,465,134.16 yuan, an increase from 1,962,747,814.92 yuan in the same period last year[173] - Net profit attributable to shareholders of the parent company was 426,071,861.54 yuan, up from 402,651,466.95 yuan in the same period last year[173] - R&D expenses for the first half of 2023 were 62,104,795.13 yuan, slightly higher than 60,286,779.43 yuan in the same period last year[173] - Sales expenses increased to 126,384,109.56 yuan from 90,332,891.19 yuan in the same period last year[173] - Financial income was -46,731,407.98 yuan, compared to an expense of 15,763,382.80 yuan in the same period last year[173] - Basic earnings per share were 0.5640 yuan, down from 0.6384 yuan in the same period last year[173] - Interest income increased significantly to 20,115,687.37 yuan, compared to 7,233,948.63 yuan in the previous period[174] - Net profit for the period was 291,184,795.76 yuan, up from 266,020,776.21 yuan in the same period last year[174] - Operating cash flow was negative at -312,643,967.86 yuan, compared to -62,477,473.45 yuan in the previous period[175] - Investment cash flow was negative at -1,635,299,282.83 yuan, compared to -159,552,958.67 yuan in the previous period[177] - Cash and cash equivalents decreased by 1,743,479,996.59 yuan, compared to a decrease of 341,667,824.12 yuan in the previous period[177] - Sales revenue from goods and services was 2,034,917,601.65 yuan, down from 2,219,618,604.08 yuan in the previous period[175] - Payments for goods and services were 1,385,002,901.53 yuan, down from 1,602,230,413.01 yuan in the previous period[175] - Payments to employees increased to 538,048,184.32 yuan, up from 424,220,469.43 yuan in the previous period[175] - Tax payments increased to 265,066,907.13 yuan, up from 171,371,777.20 yuan in the previous period[175] - Investment income was 42,419,337.82 yuan, up from 30,284,729.04 yuan in the previous period[174] - Accounts receivable increased to 1,288,785,673.83 from 941,730,815.11, a growth of 36.8%[188] - Total current assets decreased to 6,294,276,783.27 from 8,106,877,958.50, a decline of 22.4%[188] - Long-term equity investments increased significantly to 3,937,216,159.98 from 2,445,763,731.66, a growth of 61.0%[188] - Total non-current assets rose to 4,580,564,827.17 from 3,023,154,089.29, an increase of 51.5%[188] - Total assets slightly decreased to 10,874,841,610.44 from 11,130,032,047.79, a marginal decline of 2.3%[188] - Contract liabilities decreased to 3,186,153,808.90 from 3,595,912,414.82, a reduction of 11.4%[188] - Inventory decreased to 1,652,548,922.66 from 1,720,299,071.30, a decline of 3.9%[188] - Prepayments decreased to 660,524,395.19 from 944,974,952.31, a reduction of 30.1%[188] - Other receivables decreased to 106,002,046.23 from 209,214,653.86, a decline of 49.3%[188] - Fixed assets decreased slightly to 296,715,694.74 from 304,154,419.92, a marginal decline of 2.4%[188] Shareholder Structure and Ownership - The top 10 shareholders include Shanghai Biomedical Industry Equity Investment Fund Partnership, which subscribed to 24,307,243 shares, and Guotou Zhaoshang Investment Management Co., Ltd., which also subscribed to 24,307,243 shares[116] - The total number of ordinary shareholders at the end of the reporting period is 29,074, with a 5% shareholding ratio[127] - Zheng Xiaodong, a domestic natural person, holds 34.07% of the shares, amounting to 259,189,008 shares[127] - Zheng Keqing, another domestic natural person, holds 16.52% of the shares, amounting to 125,667,408 shares[127] - Hong Kong Central Clearing Limited, an overseas legal entity, holds 4.26% of the shares, amounting to 32,432,570 shares[127] - Shanghai Biomedical Industry Equity Investment Fund Partnership holds 3.20% of the shares, amounting to 24,307,243 shares[127] - The total number of shares held by the top 10 shareholders is 268,287,652, with no changes during the reporting period[133] Dividend Policy - The company does not plan to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital[91] International Expansion and Exchange Rate Impact - The company is focusing on international expansion, with increasing export business, which may be significantly impacted by exchange rate fluctuations[33] Pharmaceutical Industry and Customer Focus - The company's main customer base is in the pharmaceutical industry, and it is enhancing quality management by integrating ICHQ9, GMP, and other pharmaceutical-related management requirements to improve customer satisfaction[36] - The pharmaceutical industry is undergoing rapid changes, leading to increased competition and a potential decline in the company's core business profitability[38] Risk Management and Governance - The company is implementing measures to improve investment decision-making, enhance governance, and mitigate risks associated with external development[39] - The company is focusing on precision management to improve efficiency, including optimizing organizational structures, processes, and IT systems to build competitive platforms in sales, R&D, manufacturing, HR, and finance[40] - The company is strengthening post-investment management of acquired businesses to maximize risk mitigation and ensure strategic alignment[41] Environmental and Social Responsibility - The company is actively using green energy, such as solar power, to reduce electricity consumption in its facilities[48] - The company has established environmental protection regulations, including energy-saving initiatives, waste management, and emergency response plans for hazardous materials[64] - The company is committed to supporting education through scholarships and providing accessible, high-quality educational opportunities for local youth[59] Product and Industry Focus - The company's products are designed for the pharmaceutical, food, and medical industries, featuring customized stainless steel equipment with environmentally friendly components and advanced SCADA systems for automation[86] Financial Reporting and Disclosure - The company's financial report for the first half of 2023 is available on the official website[132] - The company's financial data and indicators are detailed in the "Company Profile and Major Financial Indicators" section of the report[138] - The company does not have any preferred shares during the reporting period[137]

| 其它关联资金 | | 往来方与上市公 | 上市公司核算的 | 2023 | 年期初往来资 | 2023 | 年半年度往来累 | 2023 | 年半年度往 | 年半年度 2023 | 2023年半年度 | 往来形成原 | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金往来方名称 | | | | | | | | | 偿还累计发生 | 期末往来资金 | | （经营性往来、 | | 往来 | | 司的关联关系 | 会计科目 | | 金余额 | | 计发生金额 | | 来资金的利息 | | | 因 | | | | | | | | | | | | | 金额 | 余额 | | 非经营性往来） | | | 浙江东富龙生物技 | 子公司 | 其他应收款 | | 16,665.20 | | | | | 16,665.20 | - | 子公司暂借 | 非经营性往来 | | | 术有限公司 | | | | | | | | | | | 款 | | | | 上海东富龙制药设 | 子公 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-037 募集资金的存放和管理均符合相关规定，不存在违规使用募集资金的行为，不存 在改变或变相改变募集资金投向和损害股东利益的情况。 东富龙科技集团股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届监事会第三次会 议于 2023 年 8 月 17 日以电话、书面方式通知各位监事，会议于 2023 年 8 月 28 日（星期一）在公司（上海市闵行区都会路 1509 号）305 会议室以现场方式召 开。本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。本次会议由 监事会主席杨东生先生主持。公司董事会秘书列席本次会议。会议符合《公司法》 及《公司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 监事会认为：董事会编制和审核公司《2023 年半年度报告》全文及摘要的 程序符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规 定，报告内容 ...